University Sorbonne Paris Cité, Paris Diderot University, Inserm U1149 / ERL 8252, Inflammation Research Center (CRI), Laboratory of Excellence GR-Ex, Paris, France.
AP-HP, Centre Français des Porphyries, Hôpital Louis Mourier, Colombes, France.
Haematologica. 2018 Apr;103(4):587-596. doi: 10.3324/haematol.2017.177816. Epub 2018 Jan 5.
Gaucher disease (GD) is an inherited deficiency of glucocerebrosidase leading to accumulation of glucosylceramide in tissues such as the spleen, liver, and bone marrow. The resulting lipid-laden macrophages lead to the appearance of "Gaucher cells". Anemia associated with an unexplained hyperferritinemia is a frequent finding in GD, but whether this pathogenesis is related to an iron metabolism disorder has remained unclear. To investigate this issue, we explored the iron status of a large cohort of 90 type I GD patients, including 66 patients treated with enzyme replacement therapy. Ten of the patients treated with enzyme replacement were followed up before and during treatment. Serum levels of hepcidin, the iron regulatory peptide, remained within the physiological range, while the transferrin saturation was slightly decreased in children. Inflammation-independent hyperferritinemia was found in 65% of the patients, and Perl's staining of the spleen and marrow smear revealed iron accumulation in Gaucher cells. Treated patients exhibited reduced hyperferritinemia, increased transferrin saturation and transiently increased systemic hepcidin. In addition, the hepcidin and ferritin correlation was markedly improved, and, in most patients, the hemoglobin level was normalized. To further explore eventual iron sequestration in macrophages, we produce a Gaucher cells model by treating the J774 macrophage cell line with a glucocerebrosidase inhibitor and showed induced local hepcidin and membrane retrieval of the iron exporter, ferroportin. These data reveal the involvement of Gaucher cells in abnormal iron sequestration, which may explain the mechanism of hyperferritinemia in GD patients. Local hepcidin-ferroportin interaction was involved in this pathogenesis.
戈谢病(GD)是一种葡糖脑苷脂酶缺乏症,导致葡糖脑苷脂在脾脏、肝脏和骨髓等组织中积累。由此产生的富含脂质的巨噬细胞导致“戈谢细胞”的出现。与不明原因的高血铁蛋白血症相关的贫血是 GD 的常见表现,但这种发病机制是否与铁代谢紊乱有关尚不清楚。为了研究这个问题,我们研究了 90 例 I 型 GD 患者的大队列的铁状态,其中包括 66 例接受酶替代治疗的患者。10 例接受酶替代治疗的患者在治疗前后进行了随访。铁调节肽-铁蛋白的血清水平仍在生理范围内,而儿童的转铁蛋白饱和度略有下降。65%的患者存在与炎症无关的高血铁蛋白血症,脾脏和骨髓涂片的 Perl 染色显示 Gaucher 细胞中铁的积累。治疗后的患者表现为高血铁蛋白血症降低,转铁蛋白饱和度增加,系统性铁蛋白暂时增加。此外,铁蛋白和铁蛋白的相关性明显改善,大多数患者的血红蛋白水平正常化。为了进一步探讨巨噬细胞中铁的蓄积,我们用葡糖脑苷脂酶抑制剂处理 J774 巨噬细胞系,建立了戈谢细胞模型,并显示局部铁蛋白诱导和铁输出蛋白( ferroportin )膜回收。这些数据揭示了 Gaucher 细胞参与异常铁蓄积,这可能解释了 GD 患者高血铁蛋白血症的机制。局部铁蛋白- ferroportin 相互作用参与了这种发病机制。